Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

Technology appraisal guidance
Reference number: TA285
Published: 22 May 2013

History

Documents created during the development process.

Review proposal consultation

Review proposal consultation
Stakeholder matrix (MSWord 35 KB)

Published:

25 April 2016
Review proposal paper (PDF 249 KB)

Published:

25 April 2016

Background information

TA285 Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: press release information

Ovarian cancer, fallopian tube and primary peritoneal cancer (recurrent advanced) - bevacizumab equality impact assessment - guidance review - May 2013

Ovarian cancer, fallopian tube and primary peritoneal cancer (recurrent advanced) - bevacizumab equality impact assessment - guidance review - May 2013
Ovarian cancer, fallopian tube and primary peritoneal cancer (recurrent advanced) - bevacizumab equality impact assessment - guidance review - May 2013 (PDF 169 KB)

Published:

24 May 2013

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination information
Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination document
Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination document (PDF 282 KB)

Published:

19 April 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: evaluation report information
Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: evaluation report (PDF 547 KB)

Published:

19 April 2013

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appraisal consultation

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appraisal consultation
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appraisal consultation document information
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: evaluation report
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: pre-meeting briefing
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: pre-meeting briefing (PDF 400 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Evidence Review Group report
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Evidence Review Group report (PDF 2.81 MB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: ERG report - factual accuracy check
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: ERG report - factual accuracy check (PDF 125 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: erratum to the ERG report
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: erratum to the ERG report (PDF 248 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: additional analyses
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: additional analyses (PDF 224 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Roche
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Roche (PDF 2.46 MB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: clarification
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: NICE clarification letter
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: NICE clarification letter (PDF 323 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: manufacturer response to the NICE clarification letter
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: manufacturer response to the NICE clarification letter (PDF 476 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: patient group, professional group and NHS organisation submission statements
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Royal College of Nursing
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Royal College of Nursing (PDF 4.5 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Royal College of Physicians
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Royal College of Physicians (PDF 115 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Target Ovarian Cancer
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Target Ovarian Cancer (PDF 80 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: expert written personal statements
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Gourley
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Gourley (PDF 26 KB)

Published:

01 January 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Lederman
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Lederman (PDF 32 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Tate
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Tate (PDF 33 KB)

Published:

01 February 2013
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Chillingworth
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Chillingworth (PDF 123 KB)

Published:

01 February 2013

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - final scope

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - final scope
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - final scope (PDF 51 KB)

Published:

03 August 2012

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - final matrix

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - final matrix
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - final matrix (PDF 58 KB)

Published:

03 August 2012

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix (PDF 174 KB)

Published:

03 August 2012

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: equality impact assessment form - scoping

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: equality impact assessment form - scoping
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: equality impact assessment form - scoping (PDF 30 KB)

Published:

01 August 2012

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - draft scope for consultation (pre-referral) - May 2011

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - draft scope for consultation (pre-referral) - May 2011
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - draft scope for consultation (pre-referral) - May 2011 (PDF 57 KB)

Published:

17 October 2011

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - provisional matrix (pre-referral) - May 2011

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - provisional matrix (pre-referral) - May 2011
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - provisional matrix (pre-referral) - May 2011 (PDF 66 KB)

Published:

17 October 2011